Cargando…
In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70)
PURPOSE: To study in vivo effects of the human monoclonal TSH receptor (TSHR) autoantibodies M22 (stimulating type) and K1-70 (blocking type) on thyroid hormone levels in rats. METHODS: Serum levels of total T4, free T4, M22 and K1-70 were measured following intramuscular injection of M22 IgG (2–4 μ...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389019/ https://www.ncbi.nlm.nih.gov/pubmed/26000124 http://dx.doi.org/10.1007/s13317-011-0025-9 |
_version_ | 1782365469760552960 |
---|---|
author | Furmaniak, Jadwiga Sanders, Jane Young, Stuart Kabelis, Katarzyna Sanders, Paul Evans, Michele Clark, Jill Wilmot, Jane Rees Smith, Bernard |
author_facet | Furmaniak, Jadwiga Sanders, Jane Young, Stuart Kabelis, Katarzyna Sanders, Paul Evans, Michele Clark, Jill Wilmot, Jane Rees Smith, Bernard |
author_sort | Furmaniak, Jadwiga |
collection | PubMed |
description | PURPOSE: To study in vivo effects of the human monoclonal TSH receptor (TSHR) autoantibodies M22 (stimulating type) and K1-70 (blocking type) on thyroid hormone levels in rats. METHODS: Serum levels of total T4, free T4, M22 and K1-70 were measured following intramuscular injection of M22 IgG (2–4 μg/animal), K1-70 IgG (10–200 μg/animal) or both into rats. Thyroid pathology was assessed in M22-injected rats. RESULTS: Serum levels of total T4 and free T4 increased in a dose-dependent manner following injection of M22 IgG. Thyroid follicular cell hypertrophy was dependent on the dose of M22 IgG. K1-70 IgG caused a dose dependent decrease of total T4 and free T4 levels in rats receiving K1-70 only. The stimulating effects of M22 IgG on T4 levels in rats were completely inhibited by K1-70 IgG. CONCLUSION: M22 is a potent stimulator of thyroid hormone secretion in vivo. In contrast, K1-70 inhibits thyroid hormone secretion in vivo. Furthermore, K1-70 has the ability to inhibit the stimulating activity of M22 in vivo and as such has potential as a new drug to block TSHR stimulation by autoantibodies in Graves’ disease. |
format | Online Article Text |
id | pubmed-4389019 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-43890192015-05-21 In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70) Furmaniak, Jadwiga Sanders, Jane Young, Stuart Kabelis, Katarzyna Sanders, Paul Evans, Michele Clark, Jill Wilmot, Jane Rees Smith, Bernard Auto Immun Highlights Original Article PURPOSE: To study in vivo effects of the human monoclonal TSH receptor (TSHR) autoantibodies M22 (stimulating type) and K1-70 (blocking type) on thyroid hormone levels in rats. METHODS: Serum levels of total T4, free T4, M22 and K1-70 were measured following intramuscular injection of M22 IgG (2–4 μg/animal), K1-70 IgG (10–200 μg/animal) or both into rats. Thyroid pathology was assessed in M22-injected rats. RESULTS: Serum levels of total T4 and free T4 increased in a dose-dependent manner following injection of M22 IgG. Thyroid follicular cell hypertrophy was dependent on the dose of M22 IgG. K1-70 IgG caused a dose dependent decrease of total T4 and free T4 levels in rats receiving K1-70 only. The stimulating effects of M22 IgG on T4 levels in rats were completely inhibited by K1-70 IgG. CONCLUSION: M22 is a potent stimulator of thyroid hormone secretion in vivo. In contrast, K1-70 inhibits thyroid hormone secretion in vivo. Furthermore, K1-70 has the ability to inhibit the stimulating activity of M22 in vivo and as such has potential as a new drug to block TSHR stimulation by autoantibodies in Graves’ disease. Springer International Publishing 2011-09-14 /pmc/articles/PMC4389019/ /pubmed/26000124 http://dx.doi.org/10.1007/s13317-011-0025-9 Text en © Springer-Verlag 2011 |
spellingShingle | Original Article Furmaniak, Jadwiga Sanders, Jane Young, Stuart Kabelis, Katarzyna Sanders, Paul Evans, Michele Clark, Jill Wilmot, Jane Rees Smith, Bernard In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70) |
title | In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70) |
title_full | In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70) |
title_fullStr | In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70) |
title_full_unstemmed | In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70) |
title_short | In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70) |
title_sort | in vivo effects of a human thyroid-stimulating monoclonal autoantibody (m22) and a human thyroid-blocking autoantibody (k1-70) |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389019/ https://www.ncbi.nlm.nih.gov/pubmed/26000124 http://dx.doi.org/10.1007/s13317-011-0025-9 |
work_keys_str_mv | AT furmaniakjadwiga invivoeffectsofahumanthyroidstimulatingmonoclonalautoantibodym22andahumanthyroidblockingautoantibodyk170 AT sandersjane invivoeffectsofahumanthyroidstimulatingmonoclonalautoantibodym22andahumanthyroidblockingautoantibodyk170 AT youngstuart invivoeffectsofahumanthyroidstimulatingmonoclonalautoantibodym22andahumanthyroidblockingautoantibodyk170 AT kabeliskatarzyna invivoeffectsofahumanthyroidstimulatingmonoclonalautoantibodym22andahumanthyroidblockingautoantibodyk170 AT sanderspaul invivoeffectsofahumanthyroidstimulatingmonoclonalautoantibodym22andahumanthyroidblockingautoantibodyk170 AT evansmichele invivoeffectsofahumanthyroidstimulatingmonoclonalautoantibodym22andahumanthyroidblockingautoantibodyk170 AT clarkjill invivoeffectsofahumanthyroidstimulatingmonoclonalautoantibodym22andahumanthyroidblockingautoantibodyk170 AT wilmotjane invivoeffectsofahumanthyroidstimulatingmonoclonalautoantibodym22andahumanthyroidblockingautoantibodyk170 AT reessmithbernard invivoeffectsofahumanthyroidstimulatingmonoclonalautoantibodym22andahumanthyroidblockingautoantibodyk170 |